Znanstveni rad - Izvorni znanstveni rad
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Frontiers in Immunology, 11 (2021); 613954. https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka; Jagasia, Madan; Beohou, Eric; van der Werf, Steffie; Blaise, Didier; Kanfer, Edward; Milpied, Noel; Reményi, Péter; Ciceri, Fabio; Bourhis, Jean H.; Chevallier, Patrice; Solano, Carlos; Socié, Gerard; Bruno, Benedetto; Rambaldi, Alessandro; Castagna, Luca; Kröger, Nicolaus; Corradini, Paolo; Afanasyev, Boris; Ladetto, Marco; Niederwieser, Dietger; Scheid, Christof; Sengeloev, Henrik; Kroschinsky, Frank; Yakoub-Agha, Ibrahim; Schoemans, Helene; Koenecke, Christian; Penack, Olaf; Perić, Zinaida; Greinix, Hildegard; Duarte, Rafael F.; Basak, Grzegorz W. Više autora...

Citirajte ovaj rad

Tomaszewska, A., Jagasia, M., Beohou, E., van der Werf, S., Blaise, D., Kanfer, E. ... Basak, G. W. (2021). Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology, 11.. doi: 10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology, vol. 11, 2021. https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology 11 (2021). https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, A., et al. (2021) 'Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies', Frontiers in Immunology, 11. doi: 10.3389/fimmu.2020.613954

Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, i sur.. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology [Internet]. 02.2021. [pristupljeno 06.10.2024.];11. doi: 10.3389/fimmu.2020.613954

A. Tomaszewska, et al., "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies", Frontiers in Immunology, vol. 11, Veljača 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:878916. [Citirano: 06.10.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.